Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S de Bono

Showing results (231-240 of 426) with videos related to

Pageof 43
Sort By:
British Journal of Cancer|February 27, 2015
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agentsM Crespo, G van Dalum, R Ferraldeschi, et al.
Clinical Genitourinary Cancer|March 28, 2017
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL TrialJoshi J Alumkal, Simon Chowdhury, Yohann Loriot, et al.
Molecules (Basel, Switzerland)|December 23, 2023
Bench to Bedside Development of [<sup>18</sup>F]Fluoromethyl-(1,2-<sup>2</sup>H<sub>4</sub>)choline ([<sup>18</sup>F]D4-FCH)Amarnath Challapalli, Tara D Barwick, Suraiya R Dubash, et al.
British Journal of Cancer|July 3, 2008
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancerG Attard, J Clark, L Ambroisine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2008
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone drivenGerhardt Attard, Alison H M Reid, Timothy A Yap, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 25, 2014
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancerR Leibowitz-Amit, A J Templeton, A Omlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2013
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumorsBalaji Venugopal, Richard Baird, Rebecca S Kristeleit, et al.
Journal of Hematology & Oncology|January 7, 2014
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumorsL Rhoda Molife, Li Yan, Joanna Vitfell-Rasmussen, et al.
European Urology|July 13, 2016
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302Johann S de Bono, Matthew R Smith, Fred Saad, et al.
Oncotarget|May 4, 2018
Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patientsAfroditi Nanou, Frank A W Coumans, Guus van Dalum, et al.
Pageof 43

Showing results (231-240 of 426) with videos related to

Sort By:
Pageof 43
British Journal of Cancer|February 27, 2015
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agentsM Crespo, G van Dalum, R Ferraldeschi, et al.
Clinical Genitourinary Cancer|March 28, 2017
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL TrialJoshi J Alumkal, Simon Chowdhury, Yohann Loriot, et al.
Molecules (Basel, Switzerland)|December 23, 2023
Bench to Bedside Development of [<sup>18</sup>F]Fluoromethyl-(1,2-<sup>2</sup>H<sub>4</sub>)choline ([<sup>18</sup>F]D4-FCH)Amarnath Challapalli, Tara D Barwick, Suraiya R Dubash, et al.
British Journal of Cancer|July 3, 2008
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancerG Attard, J Clark, L Ambroisine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2008
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone drivenGerhardt Attard, Alison H M Reid, Timothy A Yap, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 25, 2014
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancerR Leibowitz-Amit, A J Templeton, A Omlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2013
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumorsBalaji Venugopal, Richard Baird, Rebecca S Kristeleit, et al.
Journal of Hematology & Oncology|January 7, 2014
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumorsL Rhoda Molife, Li Yan, Joanna Vitfell-Rasmussen, et al.
European Urology|July 13, 2016
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302Johann S de Bono, Matthew R Smith, Fred Saad, et al.
Oncotarget|May 4, 2018
Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patientsAfroditi Nanou, Frank A W Coumans, Guus van Dalum, et al.
Pageof 43